Rielly-Gauvin Katherine sold $4.1M of LQDA
Rielly-Gauvin Katherine sold 55,182 shares of Liquidia Corp (LQDA) at an average of $74.07 ($72.23–$74.99, $4.09M total) across 2 trades over 2026-08-19 to 2026-08-20 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The director's sale reduces insider ownership, which may be interpreted as a neutral to slightly negative signal for the stock.
Market read
Primary relevance is to LQDA shareholders; limited broader market impact.
What to watch
Potential upcoming clinical trial milestones could offset any negative sentiment from the sale.
Background
SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.
Ticker impact
Director Katherine Rielly-Gauvin sold 55,182 shares for $4.09M via a 10b5‑1 plan, reducing her stake to 44,637 shares.
Modest short‑term dip, likely within normal volatility range.
Director sales of this size are material for a micro‑cap but not large enough to trigger a sharp move; market may view it as routine.
Market effects
Minimal impact on the broader biotech sector; insider activity is company‑specific.
No regional effect; limited to investors tracking LQDA.
Low global relevance.
Counterpoint
The sale could be a pre‑planned liquidity event unrelated to fundamentals, so price may remain stable.
Key entities
- CompanyLiquidia Corp
Biopharmaceutical company developing drug delivery platforms.
- InsiderKatherine Rielly‑Gauvin
Director of Liquidia Corp.
